S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)

Biogen (BIIB) Stock Price, News & Analysis

$215.63
-0.71 (-0.33%)
(As of 04:37 PM ET)
Today's Range
$214.00
$217.57
50-Day Range
$212.02
$251.68
52-Week Range
$211.01
$319.76
Volume
1.77 million shs
Average Volume
1.18 million shs
Market Capitalization
$31.34 billion
P/E Ratio
27.02
Dividend Yield
N/A
Price Target
$305.68

Biogen MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
42.2% Upside
$305.68 Price Target
Short Interest
Healthy
1.84% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.39
Upright™ Environmental Score
News Sentiment
0.32mentions of Biogen in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$182,213 Sold Last Quarter
Proj. Earnings Growth
15.63%
From $15.48 to $17.90 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.99 out of 5 stars

Medical Sector

5th out of 938 stocks

Biological Products, Except Diagnostic Industry

3rd out of 154 stocks

BIIB stock logo

About Biogen Stock (NASDAQ:BIIB)

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BIIB Stock Price History

BIIB Stock News Headlines

Are These 5 Undervalued Stocks Ready to Break Out? (BIIB)
Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices.
BIIB May 2024 230.000 call
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Forecasting The Future: 18 Analyst Projections For Biogen
Biogen (NASDAQ:BIIB) Reaches New 1-Year Low at $215.35
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
BIIB May 2024 240.000 call
25 Most Stressed Cities in the United States
Eisai: All About Lenvima And Leqembi
BIIB Mar 2024 300.000 call
ABCL Oct 2024 6.000 call
See More Headlines
Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/13/2024
Today
3/28/2024
Next Earnings (Estimated)
4/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BIIB
CUSIP
09062X10
Employees
7,570
Year Founded
1978

Price Target and Rating

Average Stock Price Target
$305.68
High Stock Price Target
$373.00
Low Stock Price Target
$240.00
Potential Upside/Downside
+41.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
27 Analysts

Profitability

Net Income
$1.16 billion
Pretax Margin
13.19%

Debt

Sales & Book Value

Annual Sales
$9.84 billion
Cash Flow
$18.80 per share
Book Value
$102.14 per share

Miscellaneous

Free Float
144,489,000
Market Cap
$31.45 billion
Optionable
Optionable
Beta
-0.03

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Christopher A. Viehbacher (Age 63)
    President, CEO & Director
    Comp: $487.94k
  • Mr. Michael R. McDonnell CPA (Age 60)
    Executive VP & CFO
    Comp: $2.12M
  • Ms. Nicole Murphy
    Head of Pharmaceutical Operations & Technology
  • Ms. Susan H. Alexander Esq.Ms. Susan H. Alexander Esq. (Age 67)
    Executive VP & Chief Legal Officer
    Comp: $2.2M
  • Dr. Ginger Gregory (Age 56)
    Executive VP & Chief Human Resources Officer
    Comp: $1.59M
  • Ms. Robin C. Kramer (Age 58)
    Senior VP & Chief Accounting Officer
  • Mr. Charles E. Triano
    Senior VP & Head of Investor Relations
  • Ms. Natacha Gassenbach
    Chief Communication Officer & Head of Corporate Affairs
  • Mr. Adam Keeney Ph.D.
    Executive VP & Head of Corporate Development
  • Ms. Alisha A. Alaimo
    President & Head of North America

Should I Buy Biogen Stock? BIIB Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Biogen was last updated on Wednesday, March 27, 2024 at 10:59 PM.

Pros

Here are some ways that investors could benefit from investing in Biogen Inc.:

  • Biogen Inc. offers a diverse portfolio of therapies for treating neurological and neurodegenerative diseases, including cutting-edge treatments like ADUHELM for Alzheimer's disease.
  • The company has a strong pipeline of products under development for various conditions, indicating potential future growth and revenue streams.
  • Biogen's collaboration and license agreements with reputable companies like Genentech and Samsung Bioepis enhance its research and development capabilities.
  • Recent positive developments in the company's product offerings have the potential to drive stock price growth and investor returns.
  • Biogen's focus on biotechnology and biological products positions it well in the healthcare industry, which is known for innovation and growth potential.

Cons

Investors should be bearish about investing in Biogen Inc. for these reasons:

  • Regulatory challenges and uncertainties in the healthcare sector can impact the approval and commercial success of Biogen's products, leading to potential setbacks.
  • Competition in the biotechnology industry is intense, with other companies also developing treatments for similar diseases, which could affect Biogen's market share and profitability.
  • Market volatility and macroeconomic factors can influence the stock price of Biogen, making it susceptible to fluctuations and investor sentiment changes.
  • Investing in biotechnology companies like Biogen carries inherent risks due to the nature of drug development, including clinical trial failures and regulatory hurdles.
  • Changes in healthcare policies and regulations, both domestically and internationally, can impact Biogen's operations and financial performance, creating uncertainties for investors.

BIIB Stock Analysis - Frequently Asked Questions

Should I buy or sell Biogen stock right now?

27 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 8 hold ratings and 19 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BIIB shares.
View BIIB analyst ratings
or view top-rated stocks.

What is Biogen's stock price target for 2024?

27 analysts have issued 12-month target prices for Biogen's shares. Their BIIB share price targets range from $240.00 to $373.00. On average, they expect the company's stock price to reach $305.68 in the next year. This suggests a possible upside of 42.2% from the stock's current price.
View analysts price targets for BIIB
or view top-rated stocks among Wall Street analysts.

How have BIIB shares performed in 2024?

Biogen's stock was trading at $258.77 at the beginning of 2024. Since then, BIIB stock has decreased by 16.9% and is now trading at $214.96.
View the best growth stocks for 2024 here
.

When is Biogen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 23rd 2024.
View our BIIB earnings forecast
.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) posted its quarterly earnings results on Tuesday, February, 13th. The biotechnology company reported $2.95 EPS for the quarter, missing the consensus estimate of $3.18 by $0.23. The biotechnology company had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.47 billion. Biogen had a trailing twelve-month return on equity of 14.91% and a net margin of 11.81%. During the same quarter last year, the business posted $4.05 EPS.
Read the conference call transcript
.

What guidance has Biogen issued on next quarter's earnings?

Biogen updated its FY 2024 earnings guidance on Tuesday, February, 13th. The company provided EPS guidance of 15.000-16.000 for the period, compared to the consensus EPS estimate of 15.650. The company issued revenue guidance of -.

What is Michel Vounatsos' approval rating as Biogen's CEO?

394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).

Who are Biogen's major shareholders?

Biogen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (11.22%), Vanguard Group Inc. (9.94%), Vanguard Group Inc. (9.91%), Wellington Management Group LLP (3.66%), Clearbridge Investments LLC (1.16%) and Legal & General Group Plc (1.08%). Insiders that own company stock include Alfred Sandrock, Brian S Posner, Eric K Rowinsky, Ginger Gregory, Priya Singhal and Susan H Alexander.
View institutional ownership trends
.

How do I buy shares of Biogen?

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Biogen have any subsidiaries?
The following companies are subsidiares of Biogen: BIIB Colombia S.A.S., Biogen (Argentina) SRL, Biogen (Bermuda) Technologies Ltd., Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (RTP) Realty LLC, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd, Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Digital Health Inc., Biogen Estonia OU, Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hong Kong Limited, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Limited, Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia S.R.L., Biogen Japan Ltd., Biogen Korea LLC, Biogen Latvia SIA, Biogen Lithuania UAB, Biogen Luxembourg Holding S.a.r.l., Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma d.o.o., Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o., Biogen Poland Sp. z.o.o., Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen Turkey Ilac Ticaret Limited Sirketi, Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Limited, Eidetica Biopharma GmbH, Fumapharm, IDEC Pharmaceuticals Corporation, NightstaRx Limited, Nightstar Europa Limited, Nightstar Inc., Nightstar Therapeutics Limited, Nightstar Therapeutics plc, Old Convergence Pharmaceuticals Limited, Panima Pharmaceuticals AG, Silver Acquisition Co. Ltd., Stromedix Inc., Stromedix Inc., Syntonix Pharmaceuticals Inc., TYSABRI, and Tungsten Bidco Limited.
Read More
This page (NASDAQ:BIIB) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners